Pharmacoeconomics in HP-related diseases: more questions than answers.
Deltenre
M
M
University Hospital Brugmann ULB/VUB, B-Brussels.
De Bruyne
I
I
Jonas
C
C
De Koster
E
E
D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D017850:Economics, Pharmaceutical / Q000706:statistics & numerical data; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D018803:Models, Economic; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use; D011899:Ranitidine / Q000191:economics / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000209:etiology / Q000517:prevention & control; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology
D000897:Anti-Ulcer Agents; D011899:Ranitidine; D009853:Omeprazole